Sanofi-Aventis pays big in new deal with Regeneron
Sanofi-Aventis and Regeneron are collaborating again, this time for the discovery, development, and sale of therapeutic antibodies using Regeneron's VelociSuite platform of technologies in a deal that could be worth over $1bn.
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.